Business
Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray
CRYSTAL LAKE, Ill., March 16, 2026--Aptar Pharma’s Intranasal Delivery System Used in Phase II Clinical Study Investigational SPONTAN® Nasal Spray
About this update from Aptargroup, Inc.
[{"type":"image","alt":"Aptar’s Intranasal Delivery System Utilized in Phase II Clinical Study of SPONTAN® Nasal Spray","displaySize":"","headline":null,"caption":"Aptar’s Intranasal Delivery System Utilized in Phase II Clinical Study of SPONTAN® Nasal Spray","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/0d79cfb472c598c0d0aa616b810da9ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h8uXfpxsH_ImKiR0zaqDnQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0d79cfb472c598c0d0aa616b810da9ff","width":480,"height":480}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f1e2fb7ef5945bc837683321f0b8b542"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9zOWPiQqTaBn4yGq67ufRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f1e2fb7ef5945bc837683321f0b8b542","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/VVharxiGKL015sbo1jbUiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/f1e2fb7ef5945bc837683321f0b8b542","width":1024,"height":512}}},{"type":"text","content":"Supporting advancement of complex intranasal therapies through clinical development","length":83,"tagName":"p","attribs":{}},{"type":"text","content":"CRYSTAL LAKE, Ill., March 16, 2026--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its proprietary nasal delivery system is being utilized in LTR Pharma Limited’s (ASX:LTP) Phase II clinical study of SPONTAN®, an investigational intranasal spray under development for the treatment of erectile dysfunction. This milestone reflects Aptar Pharma’s continued commitment to supporting intranasal drug delivery technologies and supporting the development of innovative, patient-centric therapies.","length":614,"tagName":"p"},{"type":"text","content":"LTR Pharma recently announced the dosing of the first patients in the Phase II study of SPONTAN®, which is eva...